Dong-A Socio Holdings Co., Ltd. (000640.KS)
KRW 110000.0
(4.86%)
KRW 110000.0
(4.86%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 57.98 Billion KRW | 640.12% |
| 2022 | 7.83 Billion KRW | -87.0% |
| 2021 | 60.27 Billion KRW | -62.87% |
| 2020 | 162.34 Billion KRW | 721.4% |
| 2019 | 19.76 Billion KRW | 112.05% |
| 2018 | -163.97 Billion KRW | -603.87% |
| 2017 | 32.54 Billion KRW | -78.17% |
| 2016 | 149.05 Billion KRW | 211.28% |
| 2015 | 47.88 Billion KRW | 2690.42% |
| 2014 | 1.71 Billion KRW | -88.98% |
| 2013 | 15.56 Billion KRW | -81.87% |
| 2012 | 85.87 Billion KRW | 24.07% |
| 2011 | 69.21 Billion KRW | -3.17% |
| 2010 | 71.48 Billion KRW | 12.99% |
| 2009 | 63.26 Billion KRW | 45.85% |
| 2008 | 43.37 Billion KRW | 24.77% |
| 2007 | 34.76 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 17.27 Billion KRW | 120.23% |
| 2024 Q1 | 7.84 Billion KRW | -49.03% |
| 2023 Q2 | 21.79 Billion KRW | 112.05% |
| 2023 Q1 | 10.27 Billion KRW | 148.11% |
| 2023 Q4 | 15.38 Billion KRW | -34.83% |
| 2023 FY | 57.98 Billion KRW | 640.12% |
| 2023 Q3 | 23.61 Billion KRW | 8.31% |
| 2022 Q1 | -4.56 Billion KRW | 76.1% |
| 2022 Q2 | 9.25 Billion KRW | 302.69% |
| 2022 Q3 | 25.54 Billion KRW | 175.94% |
| 2022 Q4 | -21.36 Billion KRW | -183.67% |
| 2022 FY | 7.83 Billion KRW | -87.0% |
| 2021 Q1 | 793.53 Million KRW | -99.41% |
| 2021 Q2 | 15.9 Billion KRW | 1904.67% |
| 2021 Q3 | 62.67 Billion KRW | 294.0% |
| 2021 Q4 | -19.1 Billion KRW | -130.49% |
| 2021 FY | 60.27 Billion KRW | -62.87% |
| 2020 Q2 | 6.44 Billion KRW | -23.02% |
| 2020 FY | 162.34 Billion KRW | 721.4% |
| 2020 Q1 | 8.36 Billion KRW | 388.33% |
| 2020 Q4 | 134.73 Billion KRW | 952.69% |
| 2020 Q3 | 12.79 Billion KRW | 98.66% |
| 2019 Q1 | -606.27 Million KRW | 99.68% |
| 2019 FY | 19.76 Billion KRW | 112.05% |
| 2019 Q4 | -2.9 Billion KRW | -116.62% |
| 2019 Q3 | 17.46 Billion KRW | 200.79% |
| 2019 Q2 | 5.8 Billion KRW | 1057.8% |
| 2018 Q2 | 22.62 Billion KRW | 1252.44% |
| 2018 Q1 | -1.96 Billion KRW | 50.06% |
| 2018 FY | -163.97 Billion KRW | -603.87% |
| 2018 Q4 | -187.56 Billion KRW | -6516.85% |
| 2018 Q3 | 2.92 Billion KRW | -87.08% |
| 2017 FY | 32.54 Billion KRW | -78.17% |
| 2017 Q4 | -3.93 Billion KRW | -127.45% |
| 2017 Q3 | 14.32 Billion KRW | -38.47% |
| 2017 Q2 | 23.27 Billion KRW | 2167.66% |
| 2017 Q1 | -1.12 Billion KRW | -108.29% |
| 2016 Q2 | 114.79 Billion KRW | 1319.45% |
| 2016 FY | 149.05 Billion KRW | 211.28% |
| 2016 Q4 | 13.58 Billion KRW | 7.85% |
| 2016 Q1 | 8.08 Billion KRW | 491.69% |
| 2016 Q3 | 12.59 Billion KRW | -89.03% |
| 2015 Q2 | 51.92 Billion KRW | 5417.72% |
| 2015 FY | 47.88 Billion KRW | 2690.42% |
| 2015 Q1 | -976.53 Million KRW | 65.38% |
| 2015 Q4 | -2.06 Billion KRW | -105.45% |
| 2015 Q3 | -1 Billion KRW | -101.94% |
| 2014 FY | 1.71 Billion KRW | -88.98% |
| 2014 Q3 | 1.68 Billion KRW | -49.17% |
| 2014 Q2 | 3.32 Billion KRW | 803.36% |
| 2014 Q4 | -2.82 Billion KRW | -267.11% |
| 2014 Q1 | -472.15 Million KRW | 81.95% |
| 2013 Q4 | -2.61 Billion KRW | -122.41% |
| 2013 FY | 15.56 Billion KRW | -81.87% |
| 2013 Q1 | -18.55 Billion KRW | -222.64% |
| 2013 Q2 | 6.47 Billion KRW | 134.87% |
| 2013 Q3 | 11.67 Billion KRW | 80.4% |
| 2012 FY | 85.87 Billion KRW | 24.07% |
| 2012 Q1 | 16.4 Billion KRW | 0.0% |
| 2012 Q2 | 18.89 Billion KRW | 15.22% |
| 2012 Q3 | 26.26 Billion KRW | 39.0% |
| 2012 Q4 | 15.13 Billion KRW | -42.4% |
| 2011 FY | 69.21 Billion KRW | -3.17% |
| 2011 Q3 | 21.31 Billion KRW | 1.7% |
| 2011 Q1 | 20.36 Billion KRW | 0.0% |
| 2011 Q2 | 20.96 Billion KRW | 2.93% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | 11.22 Billion KRW | -66.17% |
| 2010 FY | 71.48 Billion KRW | 12.99% |
| 2010 Q2 | 33.16 Billion KRW | 113.53% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q1 | 15.53 Billion KRW | 0.0% |
| 2009 Q3 | 20.68 Billion KRW | 41.82% |
| 2009 Q2 | 14.58 Billion KRW | 23.18% |
| 2009 Q1 | 11.84 Billion KRW | 0.0% |
| 2009 FY | 63.26 Billion KRW | 45.85% |
| 2009 Q4 | - KRW | -100.0% |
| 2008 FY | 43.37 Billion KRW | 24.77% |
| 2008 Q3 | 18.85 Billion KRW | 78.5% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q1 | 5.09 Billion KRW | 0.0% |
| 2008 Q2 | 10.56 Billion KRW | 107.15% |
| 2007 Q1 | -30.29 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | 34.76 Billion KRW | 0.0% |
| 2007 Q2 | 4.77 Billion KRW | 115.74% |
| 2007 Q3 | 9.05 Billion KRW | 89.8% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 907.552% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 197.319% |
| HANDOK Inc. | -28.79 Billion KRW | 301.37% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 789.106% |
| Yuhan Corporation | 93.5 Billion KRW | 37.985% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -421.373% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 333.715% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 60.344% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -1552.779% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 2413.645% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 2896.145% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 1381.583% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -159.661% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 907.552% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 376.92% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -1518.294% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 149.032% |
| JW Holdings Corporation | 19.02 Billion KRW | -204.786% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 173.471% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 72.714% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -56.702% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 201.159% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -847.269% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -3385.912% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -1058.691% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 907.552% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | -56.874% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 47.992% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -56.702% |
| Yuhan Corporation | 93.5 Billion KRW | 37.985% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 456.864% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 1596.294% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -847.661% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -56.702% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -206.729% |
| Korea United Pharm Inc. | 48.26 Billion KRW | -20.156% |
| CKD Bio Corp. | -24.19 Billion KRW | 339.7% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | -142.462% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | -111.345% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | -94.764% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 201.159% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | -23.362% |
| Boryung Corporation | 40.2 Billion KRW | -44.243% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 285.095% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 2413.645% |
| JW Lifescience Corporation | 28.14 Billion KRW | -106.046% |